Diaceutics PLC

OTCPK:DIUX.F Stock Report

Market Cap: US$89.7m

Diaceutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Peter Keeling

Chief executive officer

UK£363.2k

Total compensation

CEO salary percentage75.7%
CEO tenureno data
CEO ownership20.5%
Management average tenure1.8yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Peter Keeling's remuneration changed compared to Diaceutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

UK£6k

Mar 31 2023n/an/a

UK£365k

Dec 31 2022UK£363kUK£275k

UK£724k

Sep 30 2022n/an/a

UK£427k

Jun 30 2022n/an/a

UK£129k

Mar 31 2022n/an/a

UK£345k

Dec 31 2021UK£276kUK£252k

UK£561k

Sep 30 2021n/an/a

-UK£294k

Jun 30 2021n/an/a

-UK£1m

Mar 31 2021n/an/a

-UK£443k

Dec 31 2020UK£273kUK£247k

UK£263k

Sep 30 2020n/an/a

UK£2m

Jun 30 2020n/an/a

UK£3m

Mar 31 2020n/an/a

UK£2m

Dec 31 2019UK£284kUK£207k

UK£398k

Sep 30 2019n/an/a

UK£124k

Jun 30 2019n/an/a

-UK£151k

Mar 31 2019n/an/a

UK£241k

Dec 31 2018UK£100kn/a

UK£632k

Compensation vs Market: Peter's total compensation ($USD449.44K) is below average for companies of similar size in the US market ($USD740.57K).

Compensation vs Earnings: Peter's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Peter Keeling (62 yo)

no data

Tenure

UK£363,235

Compensation

Mr. Peter Keeling serves as Chief Executive Officer and Executive Director at Diaceutics PLC. He is the Founder of Diaceutics PLC. He was Co-Founder and Chief Executive at Diagnology Limited.He has an exp...

Leadership Team

NamePositionTenureCompensationOwnership
Peter Keeling
Founderno dataUK£363.24k20.47%
$ 18.4m
Nicholas Roberts
CFO & Director1.7yrsUK£180.37k0.049%
$ 43.8k
Ryan Keeling
Executive Directorno dataUK£334.27k3.55%
$ 3.2m
Julie Browne
Chief Operating Officer1.7yrsno datano data
Gillian Shaw
General Counsel1.8yrsno datano data
Jillian Beggs
Vice President of Sales & Marketing1.9yrsno datano data
Norma Thompson
Global Head of Human Resources3.2yrsno datano data
Jordan Clark
Chief Commercial Officer1.8yrsno data0.83%
$ 748.8k
Susanne Munksted
Chief Precision Medicine Officer4.8yrsno datano data
Marieke Hoefsmit
Senior Director & Head of Data Delivery Netherlands1.7yrsno datano data
Bethany Slifko
Head of Knowledge & Insight Team US1.7yrsno datano data
Sally Craig
Company Secretary3.2yrsno datano data

1.8yrs

Average Tenure

40yo

Average Age

Experienced Management: DIUX.F's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Peter Keeling
Founderno dataUK£363.24k20.47%
$ 18.4m
Nicholas Roberts
CFO & Director1.7yrsUK£180.37k0.049%
$ 43.8k
Ryan Keeling
Executive Directorno dataUK£334.27k3.55%
$ 3.2m
Graham Paterson
Independent Non-Executive Directorless than a yearno datano data
Kenneth Bloom
Member of Advisory Boardno datano datano data
Avi Kulkarni
Member of Advisory Board2.8yrsno datano data
Michael Wort
Independent Non-Executive Directorno dataUK£30.00k0.17%
$ 154.0k
Deborah Davis
Independent Non-Executive Chair2.8yrsUK£70.00k0.10%
$ 91.5k
Anthony Magliocco
Member of Advisory Boardno datano datano data
Keith Kerr
Member of Advisory Boardno datano datano data
Markus Eckstein
Member of Advisory Boardno datano datano data

2.3yrs

Average Tenure

60yo

Average Age

Experienced Board: DIUX.F's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/11/05 19:36
End of Day Share Price 2023/08/08 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Diaceutics PLC is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hayley PalmerCanaccord Genuity
Colin SmithCapital Access Group
Oliver JugginsCapital Access Group